Establishment Labs Holdings (ESTA) 2025 Earnings Call Presentation

Financial Performance and Outlook - 2025 revenue guidance is projected to be between $205 million and $210 million[26] - US revenue is expected to meaningfully exceed $35 million in 2025, including approximately $9.5 million to $10 million in 2Q[26] - The company anticipates achieving EBITDA positive in 2025 and expects to grow at over 20% for at least the next three years[26] - The company expects to achieve cash flow positive in 2026[26] US Market Strategy - The company aims to achieve over $35 million in revenue in the US in 2025[33] - Over 1000 surgeons have opened accounts, and over 75% of orders are placed via the Motiva Portal[32] - The company has placed permanent consignments in over 100 targeted accounts YTD[31] Product and Innovation - Motiva devices have been used in over 4 million procedures worldwide since 2010[13] - The company has over 210 patents approved/pending in over 20 jurisdictions[13] - The company is extending additional sizes for current portfolio and developing Ergonomix2® Platform & Mia Femtech[81] Breast Reconstruction Market - Device-based reconstruction market represents over 100,000 procedures per year, with steady procedural growth of approximately 2%[223] - Reconstruction represents approximately 25% of total breast procedures and approximately 50% of total breast revenue[225] - Reconstruction implant ASPs tend to be 25-30% higher than augmentation implants, and tissue expander ASPs can be nearly double than augmentation implants[226] GLP-1s and Aesthetics - 12% of America has or is taking GLP Medication[387] - GLP-1s are leading to new challenges such as skin laxity and volume issues, requiring unique solutions and combination treatments[397]